Literature DB >> 19173287

Large genomic rearrangements and germline epimutations in Lynch syndrome.

Annette Gylling1, Maaret Ridanpää, Outi Vierimaa, Kristiina Aittomäki, Kristiina Avela, Helena Kääriäinen, Hannele Laivuori, Minna Pöyhönen, Satu-Leena Sallinen, Carina Wallgren-Pettersson, Heikki J Järvinen, Jukka-Pekka Mecklin, Paivi Peltomäki.   

Abstract

In one-third of families fulfilling the Amsterdam criteria for hereditary nonpolyposis colorectal cancer/Lynch syndrome, and a majority of those not fulfilling these criteria point mutations in DNA mismatch repair (MMR) genes are not found. The role of large genomic rearrangements and germline epimutations in MLH1, MSH2 and MSH6 was evaluated in 2 such cohorts. All 45 index patients were mutation-negative by genomic sequencing and testing for a prevalent population-specific founder mutation, and selectively lacked MMR protein expression in tumor tissue. Eleven patients ("research cohort") represented 11 mutation-negative families among 81 verified or putative Lynch syndrome families from the nation-wide Hereditary Colorectal Cancer Registry of Finland. Thirty-four patients from 33 families ("clinic-based cohort") represented suspected Lynch syndrome patients tested for MMR gene mutations in a diagnostic laboratory during 2004-2007. Multiplex ligation-dependent probe amplification (MLPA) and methylation-specific (MS)-MLPA were used to detect rearrangements and epimutations, respectively. Large genomic deletions occurred in 12/45 patients (27%), being present in 3/25 (12%), 9/16 (56%) and 0/4 (0%) among index patients lacking MLH1, MSH2 or MSH6 expression, respectively. Germline epimutations of MLH1, one of which coexisted with a genomic deletion, occurred in 2 patients (4%) and were accompanied by monoallelic expression in mRNA. Large genomic deletions (mainly MSH2) and germline epimutations (MLH1) together explain a significant fraction of point mutation-negative families suspected of Lynch syndrome and are associated with characteristic clinical and family features. Our findings have important implications in the diagnosis and management of such families. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19173287     DOI: 10.1002/ijc.24230

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 2.  Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation.

Authors:  Megan P Hitchins
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

3.  De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.

Authors:  Ajay Goel; Thuy-Phuong Nguyen; Hon-Chiu E Leung; Takeshi Nagasaka; Jennifer Rhees; Erin Hotchkiss; Mildred Arnold; Pia Banerji; Minoru Koi; Chau-To Kwok; Deborah Packham; Lara Lipton; C Richard Boland; Robyn L Ward; Megan P Hitchins
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 4.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

5.  Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population.

Authors:  Jennifer Rhees; Mildred Arnold; C Richard Boland
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

6.  Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.

Authors:  Lucía Pérez-Carbonell; Cristina Alenda; Artemio Payá; Adela Castillejo; Víctor M Barberá; Carmen Guillén; Estefanía Rojas; Nuria Acame; Francisco J Gutiérrez-Aviñó; Antoni Castells; Xavier Llor; Montserrat Andreu; José-Luis Soto; Rodrigo Jover
Journal:  J Mol Diagn       Date:  2010-05-20       Impact factor: 5.568

7.  Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?

Authors:  Eddy H J van Roon; Marjo van Puijenbroek; Anneke Middeldorp; Ronald van Eijk; Emile J de Meijer; Dianhdra Erasmus; Kim A D Wouters; Manon van Engeland; Jan Oosting; Frederik J Hes; Carli M J Tops; Tom van Wezel; Judith M Boer; Hans Morreau
Journal:  BMC Cancer       Date:  2010-05-05       Impact factor: 4.430

8.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

Review 9.  Recent insights into the pathogenesis of colorectal cancer.

Authors:  Ajay Goel; Clement Richard Boland
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

10.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.